Advanced search
Publication Cover
Future Oncology Volume 12, 2016 - Issue 17
Submit an article Journal homepage
578
Views
0
CrossRef citations to date
0
Altmetric
Conference Report

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Part 1 – Kidney Cancer

Sebastiano Buti1 Medical Oncology Unit, University Hospital of Parma, Italy
,
Chiara Ciccarese2 Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy
,
Roberto Iacovelli2 Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy
,
Melissa Bersanelli1 Medical Oncology Unit, University Hospital of Parma, Italy
,
Marina Scarpelli3 Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, AOU Ospedali Riuniti, Ancona, Italy
,
Antonio Lopez-Beltran4 Department of Surgery, Cordoba University Medical School, Cordoba, Spain
,
Liang Cheng5 Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
,
Rodolfo Montironi3 Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, AOU Ospedali Riuniti, Ancona, Italy
,
Giampaolo Tortora2 Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy
&
Francesco Massari6 Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, ItalyCorrespondence[email protected]
 show all
Pages 1967-1970 | Received 27 Feb 2016, Accepted 01 Jun 2016, Published online: 17 Jun 2016

References

  • Motzer RJ , EscudierB, McDermottDFet al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.373(19), 1803–1813 (2015).
  • Choueiri TK , EscudierB, PowlesTet al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.373(19), 1814–1823 (2015).
  • Motzer RJ , SharmaP, McDermottDFet al. CheckMate 025 Phase III trial: outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). J. Clin. Oncol.34(Suppl. 2S), Abstract 498 (2016).
  • Escudier BJ , MotzerRJ, PowlesTet al. Subgroup analyses of METEOR, a randomized Phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). J. Clin. Oncol.34(Suppl. 2S), Abstract 499 (2016).
  • De Velasco G , XieW, DonskovFet al. Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.34(Suppl. 2S), Abstract 503 (2016).
  • Ghatalia P , GordetskyJ, BaeSet al. Association of a combined panel of tumor infiltrating lymphocytes, plasma cells, and macrophages with recurrence of localized clear cell (cc) renal cell carcinoma (RCC) undergoing surgery. J. Clin. Oncol.34(Suppl. 2S), Abstract 502 (2016).
  • Sekar RR , PatilD, PearlJet al. A novel preoperative inflammatory marker prognostic score in patients with clear cell and non-clear cell renal cell carcinoma. J. Clin. Oncol.34(Suppl. 2S), Abstract 530 (2016).
  • Ho TH , GagnonRC, LiuYet al. T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade. J. Clin. Oncol.34(Suppl. 2S), Abstract 501 (2016).
  • Voss MH , HellmannMD, ChenYet al. Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab. J. Clin. Oncol.34(Suppl. 2S), Abstract 514 (2016).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.